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Objective. Rheumatoid arthritis (RA) is charac-
terized by profound mononuclear cell (MNC) recruit-
ment into synovial tissue (ST), thought to be due in part
to tumor necrosis factor  (TNF), a therapeutic target
for RA. Although chemokines may also be involved, the
mechanisms remain unclear. We undertook this study
to examine the participation of CXCL16, a novel che-
mokine, in recruitment of MNCs to RA ST in vivo and to
determine the signal transduction pathways mediating
this process.
Methods. Using a human RA ST–SCID mouse
chimera, immunohistochemistry, enzyme-linked immu-
nosorbent assay, real-time reverse transcription–
polymerase chain reaction, flow cytometry, and in vitro
chemotaxis assays, we defined the expression and func-
tion of CXCL16 and its receptor, CXCR6, as well as the
signal transduction pathways utilized by them for MNC
homing in vitro and in vivo.
Results. CXCL16 was markedly elevated in RA
synovial fluid (SF) samples, being as high as 145 ng/ml.
Intense macrophage and lining cell staining for
CXCL16 in RA ST correlated with increased CXCL16
messenger RNA levels in RA ST compared with those in
osteoarthritis and normal ST. By fluorescence-activated
cell sorting analysis, one-half of RA SF monocytes and
one-third of memory lymphocytes expressed CXCR6. In
vivo recruitment of human MNCs to RA ST implanted
in SCID mice occurred in response to intragraft injec-
tion of human CXCL16, a response similar to that
induced by TNF. Lipofection of MNCs with antisense
oligodeoxynucleotides for ERK-1/2 resulted in a 50%
decline in recruitment to engrafted RA ST and a 5-fold
decline in recruitment to regional lymph nodes. Inter-
estingly, RA ST fibroblasts did not produce CXCL16 in
response to TNF in vitro, suggesting that CXCL16
protein may function in large part independently of
TNF.
Conclusion. Taken together, these results point to
a unique role for CXCL16 as a premier MNC recruiter
in RA and suggest additional therapeutic possibilities,
targeting CXCL16, its receptor, or its signaling pathways.
One of the earliest events in rheumatoid arthritis
(RA) is the ingress of leukocytes into inflamed synovial
tissue (ST). A number of cell-derived factors facilitate
this process, including macrophage inflammatory pro-
tein 3 (MIP-3), granulocyte–macrophage colony-
stimulating factor, monocyte chemoattractant protein 1
(MCP-1), MIP-1, epithelial neutrophil–activating pep-
tide 78 (ENA-78), fractalkine, and others (1–6). Thera-
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pies designed to block the activity or inhibit the produc-
tion of these mediators and their corresponding
receptors are currently being developed. Some chemo-
kines function in a variety of ways, including initiating
angiogenesis (6–8), binding of human immunodeficiency
virus (HIV) surface proteins (9), and directly regulating
immune responses to antigen (10). However, one of the
primary functions of chemokines is their contribution to
leukocyte homing (11).
Chemokines are redundant by nature, but they
can be subdivided into inducible chemokines produced
in response to inflammation and noninducible chemo-
kines. The first group defines chemokines that recruit
leukocytes, dendritic cells, and activated T cells to sites
of inflammation. The second group defines the nonin-
flammatory, constitutive chemokines expressed in bone
marrow, thymus, and secondary lymphoid organs. Che-
mokines in the latter group are produced for normal
physiologic leukocyte trafficking (12). However, regula-
tion of leukocyte recruitment is complex and involves
both secretion and cell surface presentation of chemo-
kines, as well as their receptors, during leukocyte differ-
entiation and activation (13). Thus, chemokines are
produced in response to a variety of stimuli. For in-
stance, in RA ST fibroblasts, interleukin-1 (IL-1) and
tumor necrosis factor  (TNF) are well-known stimuli
(14–18).
Chemokines are further subdivided into so-called
“CXC” () or “CC” () chemokines. These designations
are derived from the location of 2 adjacent amino-
terminus cysteine residues. We and others have shown
that many CC chemokines and their receptors, such as
CCR5, a receptor for the CC chemokines MIP-1 and
RANTES, are up-regulated in the RA joint (19–21). The
CXC chemokines are also active mediators of inflamma-
tion in the RA joint. Examples of this class of chemo-
kines that are important in RA include IL-8 and
ENA-78 (6,14,22,23).
Much like fractalkine, CXCL16 has a chemokine
domain without the proangiogenic “ELR” (glutamate-
leucine-arginine) motif (4,24), and it is flanked by a
typical mucin structure that is rich in serine, threonine,
and proline. Both fractalkine and CXCL16 contain a
hydrophobic transmembrane domain and a short cyto-
plasmic tail (24). Other similarities exist between
CXCL16 and fractalkine, including the expression of a
transmembrane domain suspended by a heavily glycosy-
lated mucin stalk and the fact that both proteins exist as
either membrane-associated or secreted forms. These
chemokines contain a small cytoplasmic domain with a
“YXPV” motif that is a potential tyrosine phosphoryla-
tion and SH2-binding site, and is preferentially ex-
pressed by type 1 lymphocytes. Finally, CXCL16 has a
unique receptor–ligand interaction, much like fracta-
lkine (24–26). These characteristics are important, con-
sidering the proinflammatory functions of fractalkine in
RA and in rat adjuvant-induced arthritis (AIA) (3,4).
Thus, the similar physical properties of fractalkine and
CXCL16 are likely to result in similar proinflammatory
activity.
CXCR6, the only known receptor for CXCL16, is
also known as Bonzo, TYMSTR, and STRL33, and is a
newly characterized chemokine receptor initially de-
scribed as an HIV coreceptor expressed by a subset of
memory/T effector cells, natural killer cells, and plasma
cells (26–30). The present study directly addresses the
participation of both CXCR6 and its ligand CXCL16 in
leukocyte migration in RA. CXCR6-expressing leuko-
cytes may also use this receptor to migrate into
lymphocyte-rich regions such as lymph nodes (LNs). By
expressing a receptor known to actively bind HIV,
CXCR6 lymphocytes may aid in the spread of viral
infections (24). We show here that CXCL16 contributes
to chronic inflammation, since it is highly expressed in
RA synovial fluid (SF), is a potent chemoattractant for
mononuclear cells (MNCs) in vitro, and is chemotactic
for peripheral blood mononuclear cells (PBMCs) to RA
ST and LNs in vivo.
PATIENTS AND METHODS
Patient samples. SF samples were obtained during
arthrocentesis from patients with RA, osteoarthritis (OA), and
other diseases including juvenile rheumatoid arthritis (JRA),
psoriatic arthritis (PsA), polyarthritis, spondylarthropathy, in-
flammatory myopathy, and gout. Peripheral blood (PB) sera
were also obtained from patients with arthritides (RA, OA,
JRA, PsA, polyarthritis, and gout), and PB samples were
obtained from healthy normal volunteers. STs were obtained
from RA patients undergoing total joint replacement who met
the American College of Rheumatology (formerly, the Amer-
ican Rheumatism Association) 1987 revised criteria for the
classification of RA (31). Normal STs were obtained from
fresh autopsies or from amputations. All specimens were
obtained with Institutional Review Board approval.
SCID mice. SCID/NCr mice were purchased from the
National Cancer Institute (Bethesda, MD). SCID mice were
maintained in a pathogen-free animal facility and given food
and water ad libitum.
Depletion of rheumatoid factor (RF) from sera and
SF. To avoid any possible confounding effects of RF on assays,
RF was immunodepleted from sera and SF samples using
anti-IgM antibodies coupled to agarose beads (Sigma, St.
Louis, MO) as previously described (3). Removal of RF (IgM)
was determined by randomly choosing 5 RA SF samples and
measuring RF levels before and after immunodepletion using
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an RF enzyme-linked immunosorbent assay (ELISA) kit
(RDI, Flanders, NJ). Before immunodepletion, RF levels
ranged from 5 IU/ml to 300 IU/ml. After immunodepletion, all
samples had RF levels below the detection limit of the assay
(0.031 IU/ml; data not shown). Samples immunodepleted of
RF were used in the ELISA and chemotaxis studies.
Sandwich ELISA. CXCL16 levels were measured by
coating 96-well polystyrene plates with rabbit anti-human
CXCL16 (PeproTech, Rocky Hill, NJ), followed by a blocking
step as described previously (3). All samples were added in
triplicate. Biotinylated rabbit anti-human antibody (Pepro-
Tech) was used to detect CXCL16 using a streptavidin–
peroxidase method (PharMingen, San Diego, CA), with a
tetramethylbenzidine substrate (Sigma). Assay sensitivity was
routinely 125 pg/ml, and rabbit anti-human CXCL16 antibody
demonstrated 5% cross-reactivity with other recombinant
human chemokines (data not shown).
Fluorescence-activated cell sorting (FACS) analysis.
PB samples were obtained from normal volunteers and RA
patients. SF cells were obtained from the joints of RA patients
undergoing arthrocentesis. CXCR6 expression on CD14
monocytes was evaluated by FACS analysis as previously
described (11). Briefly, cells were incubated with fluorescein
isothiocyanate (FITC)–labeled mouse anti-human CD14
(PharMingen) and mouse anti-human CXCR6 antibodies
(CXCR6 IgG; kindly provided by Millennium Pharmaceuti-
cals, Cambridge, MA). CXCR6 receptor expression was de-
tected with R-phycoerythrin (R-PE)–labeled goat anti-mouse
antibodies (Jackson ImmunoResearch, West Grove, PA). For
some studies, CXCR6 receptor expression on lymphocyte
subsets was evaluated by incubating cells with anti-CXCR6
antibodies or with energy-coupled dye–labeled anti-CD4 or
anti-CD8 antibodies (Beckman Coulter, Miami, FL) with the
addition of FITC-labeled (anti-CD45RA or anti-CD45RO)
and Cy-Chrome–labeled (anti-CD3) antibodies (PharMingen)
as previously described (5,32).
Immunohistochemistry. We performed immunohisto-
logic staining on cryosections from RA, OA, and normal STs
using immunoperoxidase and avidin–biotin technique as de-
scribed previously (3). Antibodies, including control antibod-
ies, were used at 10 g/ml. Polyclonal rabbit anti-human
CXCL16 antibodies (PeproTech) or monoclonal mouse anti-
CXCR6 antibodies were used as specific antibodies, and
tissues were counterstained with Harris’ hematoxylin. STs were
also stained with the appropriate IgG control antibodies for
comparison (CXCL16 control antibody was rabbit IgG and was
obtained from R&D Systems [Minneapolis, MN]; CXCR6
control antibody was mouse IgG2 and was obtained from
Beckman Coulter). For some immunohistologic experiments,
STs were stained with mouse anti-human CXCR6 from a
different vendor to check for staining consistency (mouse
anti-human CXCR6 was obtained from R&D Systems; control
mouse IgG2 antibody was obtained from Beckman
Coulter). Various ST cell types were evaluated for staining,
including macrophages, lymphocytes, fibroblasts, and endothe-
lial cells. Immunostaining was evaluated in a blinded manner
and graded by a pathologist as described previously (33).
For 2-color immunofluorescence histology, serial ST
sections (8 m) were cut, allowed to dry for 2 hours at room
temperature, and subsequently fixed in acetone for 10 minutes
at 4°C. Following a wash with phosphate buffered saline (PBS),
sections were blocked with 3% fetal bovine serum (FBS)/PBS
for 30 minutes at 37°C. Either mouse anti-human CXCR6
antibodies or goat anti-human CXCL16 antibodies (final con-
centration 10 g/ml; both from R&D Systems) were added as
primary antibodies and incubated for 2 hours at room temper-
ature. Mouse or goat IgG served as controls. After washing
twice with PBS, Alexa 488–labeled donkey anti-mouse or
anti-goat antibody was added and incubated at room temper-
ature for 1 hour. PE-tagged rat anti-human CD14 antibody
(diluted 1:200 in PBS; Ancell, Bayport, MN) was used to detect
CD14 macrophages. After washing with PBS, nuclei were
counterstained with 4,6-diamidino-2-phenylindole (Molecular
Probes, Eugene, OR) and coverslipped. Serial sections were
examined with a BX51 Fluorescence Microscope System using
DP Manager imaging software (Olympus America, Melville,
NY). Photographs were merged, and CXCL16 (red)– and/or
CXCR6 (red)–expressing CD14 macrophages (green) were
identified by yellow fluorescence microscopy.
Real-time reverse transcription–polymerase chain re-
action (RT-PCR) (TaqMan). Total RNA was extracted from
joints by the procedure of Chomczynski and Sacchi (34). The
final RNA was digested with DNase and with an RNase
inhibitor added. Reverse transcription was performed simulta-
neously using Superscript II reverse transcriptase (Invitrogen,
Carlsbad, CA) followed by the PCR reactions and preparation
of serial dilutions of the purified PCR products (35). PCR
primers and TaqMan fluorogenic probes were designed using
the Primer Express program, version 1.01 (Applied Biosys-
tems, Foster City, CA). For human CXCL16, the following
primers and probe sequences were designed and used: 5
primer, AAGCCATTGAGACACCAGCTG; 3 primer, AC-
CTCGCTCTGACTCCCAGA; and the probe, ACGT-
CACGCGCCGGAGCA. TaqMan probes carry a 5-FAM
reporter dye and a 3-TAMRA quencher dye (Mega Bases,
Evanston, IL). The quantity of complementary DNA (cDNA)
of the gene of interest is directly related to the fluorescence
detection of FAM. The amount of cDNA was calculated using
a comparative cycle threshold method and the standard curve
method according to Perkin Elmer ABI Prism 7700 User
Bulletin no. 2, 1997 (36). The estimated amount of the gene of
interest was normalized to the amount of GAPDH.
Isolation of human MNCs and chemotaxis. PB (100
ml) was collected from normal healthy adult volunteers to
obtain MNCs, and chemotaxis was performed as previously
outlined (3) using 48-well chemotaxis chambers (Neuroprobe,
Cabin John, MD) with a 5-mm polyvinylpyrrolidone-free poly-
carbonate filter (Poretics, Livermore, CA). Results were ex-
pressed as the number of MNCs migrating per high-power
field (hpf). For CXCL16 neutralization studies, SF samples
were preincubated either with goat anti-human CXCL16 IgG
antibody or with an equivalent amount of a corresponding
control antibody (nonspecific goat IgG; Beckman Coulter) for
1 hour at 37°C. Neutralized SF samples were assayed for
chemotactic activity for normal PBMCs. All chemotaxis assays
included Hanks’ balanced salt solution (HBSS) as the negative
control and fMLP as the positive control.
RA ST fibroblast isolation and culture. ST fibroblasts
isolated from patients with RA were cultured in 24-well plates
(Becton Dickinson, Franklin Lakes, NJ) at 100,000/ml for 24 or
48 hours at 37°C in a 5% CO2 atmosphere. RA ST fibroblasts
were grown in RPMI medium (Invitrogen, Carlsbad, CA)
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supplemented with 10% FBS/1% penicillin–streptomycin. For
some cultures, fibroblasts were grown in media containing
either TNF (30 ng/ml; Pfizer, Kalamazoo, MI) or IL-1 (30
ng/ml; Pfizer). Supernatants were assayed for CXCL16 and
control chemokines.
Cell culture, cell lysis, immunoblotting, and immuno-
precipitation. Cell lysis and immunoblotting were performed
as described previously (37,38). Briefly, freshly isolated human
MNCs were incubated in 6-well plates for at least 12 hours
(2  106/well) in serum-free RPMI 1640 prior to stimulation
with 10 nM CXCL16 for various time periods. Immunoprecipi-
tation was performed according to the protocol of Roche
(Basel, Switzerland). Protein A–agarose or protein G–agarose
(Roche) was washed twice with 1 ml of lysis buffer. MNC lysate
(400 g) was added to the washed protein A–agarose or
protein G–agarose for 1 hour at 4°C. After centrifugation,
supernatant was incubated with 7 l of antiphosphotyrosine
antibody (Cell Signaling Technology, Beverly, MA) and 50 l
of protein A–agarose or protein G–agarose overnight at 4°C.
Suspensions were washed twice with lysis buffer. Thereafter,
pellets were resuspended in 2 Laemmli sample buffer and
boiled for 3 minutes. Supernatants were used in Western blot
analysis.
Sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) and Western blotting. Protein lysate
(15–20 g) was run on SDS-PAGE gels and transblotted to
nitrocellulose membranes using a semidry transblotting appa-
ratus (Bio-Rad, Hercules, CA). Nitrocellulose membranes
were blocked with 5% nonfat milk in Tris buffered saline–
Tween 20 (TBST) for 60 minutes at room temperature. Blots
were incubated overnight at 4°C with optimally diluted specific
primary antibody in TBST containing 5% nonfat milk. Phos-
phorylation state–specific antibodies to ERK-1/2 (Cell Signal-
ing Technology), Src (BioSource International, Camarillo,
CA), and Raf-1 (BioSource International) were used as pri-
mary antibodies. Blots were washed 3 times and incubated in
horseradish peroxidase–conjugated antibody (1:10,000 dilu-
tions) for 1 hour at room temperature. Protein bands were
detected using enhanced chemiluminescence (GE Healthcare,
Piscataway, NJ) in accordance with the manufacturer’s instruc-
tions. Blots were scanned and analyzed for band intensities
using UN-SCAN-ITJ version 5.1 software (Silk Scientific,
Orem, UT).
Generating human ST–SCID mouse chimeras. To
generate chimeras, we obtained human ST from RA patients
undergoing joint replacement. SCID/NCr mice (6–8 weeks
old), having a B lymphocyte and T lymphocyte defect, were
anesthetized, and graft beds were prepared subcutaneously in
the backs (behind the left ear) of mice. One RA ST specimen
(1  1  0.05 cm) was implanted per animal, and the wound
was gently sutured. Grafts were allowed to “take” and were
used 4–6 weeks after transplantation. Only those animals
without gross evidence of inflammation or rejection were used.
After engraftment, freshly isolated human MNCs were
dye-tagged with PKH26 fluorescent dye (Sigma, St. Louis,
MO). Cytospins were prepared to determine successful label-
ing of cells using a fluorescence microscope with a 550-nm
filter. Labeled cells (5  106) were injected intravenously (IV)
via the tail vein, and 48 hours later, animals were killed and
grafts and LNs were removed and snap-frozen in liquid
nitrogen. Cryosections (10-m thick) were examined in a
blinded manner for cell homing using a fluorescence micro-
scope at 550 nm. Migrating fluorescent MNCs were quantified
in grafts and LNs by counting the total number of cells per hpf
in at least 3 sections per tissue. To examine homing of MNCs
in response to chemotactic stimuli, we injected 1 g recombi-
nant human CXCL16 or 200 ng TNF directly into implanted
grafts prior to IV injection of labeled cells. This is done by
gently palpating the mouse around the scruff of the neck for
engrafted RA ST and carefully injecting the needle directly
into the grafts. The concentrations of intragraft-injected cyto-
kines were those previously shown to be effective in vivo (39).
Control chimeras received labeled cells but no stimulus.
Transient transfection of human MNCs. Isolated hu-
man PBMCs were plated overnight in 6-well plates with
serum-free RPMI 1640 medium and subsequently transfected
using Lipofectin reagent (Invitrogen). Oligodeoxynucleotide
(ODN) DNA (10 M) and Lipofectin (5 l) were incubated
separately in 100 l of serum-free medium for 30 minutes.
Solutions were mixed gently, and 880 l of medium was
added. A DNA–Lipofectin mixture was added to the preincu-
bated MNCs with an additional incubation of at least 5 hours
before use for the in vitro and in vivo signaling studies. For
transient transfection of human MNCs, the following sense
and antisense ODNs were used with subsequent CXCL16
stimulation for in vivo migration assays: ERK-1/2 sense, 5-
ATGGCGGCGGCGGCGGC-3 and ERK-1/2 antisense, 5-
GCCGCCGCCGCCGCCAT-3. Transfection of ODNs
peaked at 5 hours, with an efficiency routinely 80%.
Once transfected, MNCs were labeled with PKH26
dye, washed, and injected IV into RA ST–engrafted SCID
mice at a concentration of 5  106/100 l/mouse. We per-
formed viability counts on cells transfected with sense and
antisense ODNs for several signaling molecules, including
ERK-1/2 (cell viability 82% sense, 92% antisense), Src (cell
viability 98% sense, 97% antisense), and phosphatidylinositol
3-kinase (PI 3-kinase) (cell viability 97% sense, 100% anti-
sense). Cell viabilities were evaluated with at least 100 cells
counted per group. As described above, some mice received
simultaneous intragraft injections of CXCL16 (1 g/100 l per
mouse) when dye-tagged cells were administered IV.
Statistical analysis. Statistical analysis was done by
Student’s t-test. P values less than 0.05 were considered
significant.
RESULTS
Up-regulation of CXCR6 expression in CD14
monocytes and memory lymphocytes in RA SF. Normal
or RA PB monocytes expressed virtually no CXCR6,
while 50% of RA SF monocytes expressed this receptor
(Figure 1A). This suggests that monocytes in RA SF
might be a target for CXCL16. While only a small
minority of normal or RA PB CD3 lymphocytes
expressed CXCR6, a mean of 33% of RA SF CD3
lymphocytes expressed this receptor, as determined by
4-color flow cytometry (Figure 1B). Similar results were
obtained for CD3,CD8,CD45RO,CXCR6 lym-
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Figure 1. Flow cytometric analysis identifying the percentage of CD14 monocytes expressing CXCR6 (red cells in dot plots) in normal (NL)
peripheral blood (PB), PB from patients with rheumatoid arthritis (RA), and synovial fluid (SF) from RA patients. A, Representative dot plot of
CD14 monocyte CXCR6 expression with corresponding graph of results. CD14 monocytes did not significantly express CXCR6 in normal or RA
PB. However, 50% of CD14 monocytes from RA SF expressed CXCR6. B, Four-color fluorescence-activated cell sorting analysis on memory
lymphocytes (with corresponding graph of results) identifying elevated percentages of memory CD3,CD4,CD45RO,CXCR6 lymphocytes in
RA SF compared with normal and RA PB. Similar results were obtained for memory CD3,CD8,CD45RO,CXCR6 lymphocytes (data not
shown). C, CXCL16 concentrations in RA SF were significantly elevated compared with those in normal PB, RA PB, SF from patients with
osteoarthritis (OA), and other SF samples. D, Normal, OA, and RA synovial tissue (ST) CXCL16 mRNA expression was also evaluated by real-time
reverse transcription–polymerase chain reaction. RA ST had elevated expression of CXCL16 mRNA, indicating that factors in the RA joint support
CXCL16 expression at the level of transcription. E, Fibroblasts are one source of CXCL16 in RA. RA fibroblasts produced CXCL16 after culture
for 24 or 48 hours and did not respond significantly to exogenous cytokine (tumor necrosis factor  [TNF] or interleukin-1 [IL-1]) stimulation
at either time point. Values are the mean and SEM (n  number of patient samples). Color figure can be viewed in the online issue, which is available
at http://www.arthritisrheum.org.
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phocytes (data not shown). This indicates that CXCR6
receptor expression is on both monocytes and T lympho-
cytes in the RA joint.
Elevated CXCL16 concentration in RA. We
found that the CXCL16 concentration in RA SF was
significantly elevated compared with that in OA and
Figure 2. A and C, Immunostaining of RA ST for CXCL16 and CXCR6, respectively. B and D, Staining with the IgG control antibody. Macrophages
stained positive for both CXCL16 and CXCR6 in RA ST (arrows in A and C). E and F, Phycoerythrin-tagged rat anti-human CD14 antibody was
added to detect CD14 macrophages. Photographs were merged, and CXCL16-expressing (red in E) and/or CXCR6-expressing (red in F) CD14
macrophages (green) were identified by yellow fluorescence microscopy (arrows). RA ST CD14 macrophages expressed both CXCL16 and
CXCR6. Table 1 summarizes the various cell types staining positive for CXCL16 and CXCR6 in RA, OA, and normal ST. -CXCL16  antibody
to CXCL16; -CXCR6  antibody to CXCR6 (see Figure 1 for other definitions). (Original magnification  200 in A–D;  400 in E and F.)
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other SF samples (P  0.05) and 8 times greater than that
in sera from normal healthy people (Figure 1C). These
results point toward a significant function of CXCL16 in
the inflammatory environment of the RA joint.
We also measured CXCL16 messenger RNA
(mRNA) expression in RA ST by real-time RT-PCR.
Normal ST as well as ST obtained from patients with OA
and RA was snap-frozen and prepared for mRNA
analysis. Samples were reverse-transcribed into cDNA
and examined for CXCL16 mRNA by real-time RT-
PCR. RA ST contained elevated levels of CXCL16
mRNA compared with normal and OA ST, confirming
that CXCL16 was up-regulated in RA joint inflamma-
tion (Figure 1D). We identified one source of CXCL16
expression by culturing RA fibroblasts for 48 hours with
and without cytokine stimulation. Figure 1E shows that
unstimulated RA fibroblasts produced significant
amounts of CXCL16 (up to 0.5 ng/ml at 24 hours and 1
ng/ml at 48 hours), which were not significantly up-
regulated with the addition of TNF or IL-1. This is
contrary to our previous findings with fractalkine and
MIP-3, since we showed that RA ST fibroblasts could
be stimulated to produce significantly elevated levels of
these chemokines when stimulated with TNF (frac-
talkine and MIP-3) or IL-1 (MIP-3) (3,5).
Expression of CXCL16 and CXCR6 in RA ST by
immunohistology. As shown in Figure 2, CXCL16 and
CXCR6 were immunolocalized in ST obtained from
patients with active RA. Figure 2A shows representative
immunostaining for CXCL16 in macrophages, while this
was not observed in RA ST stained with the IgG control
antibody (Figure 2B). Figure 2C shows RA ST stained
with antibody to CXCR6. CXCL16 and CXCR6 were
also immunolocalized primarily on macrophages in RA
ST, while RA ST stained with control IgG antibody did
not show significant reactivity (Figure 2D).
For 2-color immunofluorescence histology, serial
ST sections were cut and stained either with mouse
anti-human CXCR6 antibody or with goat anti-human
CXCL16. Alexa 488–labeled donkey anti-mouse or don-
key anti-goat antibody was also added as described in
Patients and Methods. PE-tagged rat anti-human CD14
antibody was added to detect CD14 macrophages.
Photographs were merged, and CXCL16 (red)– and/or
CXCR6 (red)–expressing CD14 macrophages (green)
were identified by yellow fluorescence microscopy (Fig-
ures 2E and F, respectively). As shown, RA ST CD14
macrophages expressed both CXCL16 and CXCR6.
Table 1 summarizes the immunostaining shown
in Figure 2. Although CXCL16 and CXCR6 were ex-
pressed in normal, OA, and RA ST, we observed
significantly elevated macrophage staining for CXCL16
Figure 3. A, CXCL16 induces chemotaxis of human mononuclear
cells in a dose-dependent manner and is maximal between concentra-
tions of 2 nM and 20 nM. B, Mononuclear cell migration was also
measured in vitro in a chemotaxis assay using RA SF as a chemotactic
agent after incubation with a neutralizing anti-CXCL16 antibody. Goat
IgG served as a negative control (sham depletion). CXCL16 depletion
resulted in an 30% reduction in RA SF–induced mononuclear cell
migration. Note the similar reductions in mononuclear cell chemotaxis
in every sample tested. Values are the mean and SEM (n  number of
cell isolations from different blood donors). hpf  high-power field;
HBSS  Hanks’ balanced salt solution (see Figure 1 for other
definitions).
Table 1. Summary of immunostaining shown in Figure 2*
CXCL16 cells, % CXCR6 cells, %
Lining cells Macrophages Lining cells Macrophages
Normal ST† 29.9  8.2 64.3  6.2 9.4  2.7 41.7  4.9
OA ST† 20.6  7.2 41.0  8.6‡ 7.2  2.9 49.6  4.5
RA ST† 78.3  6.9§ 77.5  3.0 38.1  6.6§ 72.6  4.6§
* Values are the mean  SEM. ST  synovial tissue; OA  osteoar-
thritis; RA  rheumatoid arthritis.
† CXCL16 cells were obtained from 4 healthy normal volunteers, 5
OA patients, and 4 RA patients. CXCR6 cells were obtained from 5
healthy normal volunteers, 5 OA patients, and 7 RA patients.
‡ P  0.05 versus normal and RA ST.
§ P  0.05 versus normal and OA ST.
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in RA ST compared with OA ST, and we observed
elevated macrophage staining for CXCR6 in RA ST
compared with both normal and OA ST. RA ST lining
cells, containing macrophages and fibroblasts, expressed
significantly more CXCL16 and CXCR6 than did nor-
mal or OA ST.
Induction of MNC migration by CXCL16. Nor-
mal human PBMCs were assayed for their chemotactic
response to CXCL16 in a modified Boyden chamber to
determine a proinflammatory role for CXCL16. HBSS
and fMLP served as negative and positive controls,
respectively. We found a dose-dependent migration of
Figure 4. CXCL16 activates Raf and ERK-1/2 in a time-dependent manner. Monocytes (2.5  106) were stimulated with 20 nM recombinant human
CXCL16. Cell lysates were probed for p-Raf and p–ERK-1/2 by Western blotting, showing a marked increase in phosphorylation after 5 and 15
minutes, respectively. A, Representative blots for both p-Raf and p–ERK-1/2. B, Graphs corresponding to blots in A. Values are the mean and SEM
(n  number of blood donors). C, Chemotaxis for human monocytes was also measured in the presence of signaling pathway inhibitors (inh). Values
are the mean and SEM (n  4–7 donors per group). hpf  high-power field; HBSS  Hanks’ balanced salt solution; PP2  a Src inhibitor; PD 
PD98059 (a MAPK inhibitor); SB  SB203508 (a p38 MAPK inhibitor).
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human MNCs to CXCL16, with a peak between 2 nM
(20 ng/ml) and 20 nM (200 ng/ml) (Figure 3A). These
levels were consistent with those found in RA SF
(mean  SEM 44.4  4.4 ng/ml). To determine the
participation of CXCL16 in MNC migration in RA, RA
SF samples containing average levels of CXCL16 (45
ng/ml) were incubated with anti-human CXCL16 anti-
body. SF samples were then tested in an in vitro
migration assay and compared with sham-depleted con-
trols. RA SF samples showed a 28% decrease (P  0.05)
in MNC migratory activity after incubation with neutral-
izing antibody to CXCL16 (Figure 3B).
Activation of Raf and ERK-1/2 in monocytes by
CXCL16. To determine the signaling pathways mediat-
ing CXCL16 function, isolated normal human mono-
cytes were cultured overnight and stimulated with
CXCL16 for various time periods. Cell lysates were
prepared and probed with anti–phospho–ERK-1/2 and
anti–phospho-Raf by Western blotting. The blots were
stripped and reprobed with -actin to confirm equal
loading of the samples. Monocyte stimulation with
CXCL16 induced a marked increase in an early phos-
phorylation of Raf at 5 minutes and of ERK-1/2 at 15
minutes (Figure 4A). The graphs of 3 experiments with
Raf and 5 experiments with ERK-1/2 are also shown
(Figure 4B). These results were consistent with MAPK
signaling, since Raf is upstream of ERK-1/2, and they
indicated that CXCL16 may induce some of its proin-
flammatory properties through this pathway.
To further analyze the relevance of the MAPK
pathway for monocyte recruitment, migration assays
were performed with 20 nM CXCL16 in the presence of
various signaling pathway inhibitors at a final concentra-
tion of 10 M (40). As shown in Figure 4C, monocyte
migration was significantly blocked by PP2 (an inhibitor
of Src), by PD98059 (a MAPK inhibitor), and by
SB203508 (a p38 MAPK inhibitor), suggesting partici-
pation of Src and MAPK pathways for monocyte che-
motaxis toward CXCL16 in vitro.
Recruitment by CXCL16 of MNCs in vivo to
engrafted human ST in a SCID mouse chimera. To test
MNC migration in vivo, we used a human ST–SCID
mouse chimera. After 4–6 weeks, animals engrafted with
human RA ST were killed. Well-engrafted tissues with
no signs of rejection were observed and were used at this
time point (Figure 5A). To determine homing of normal
human MNCs, freshly isolated cells were dye-tagged
with PKH26, and 5  106 cells/100 l/mouse were
injected IV via the tail vein 48 hours before mice were
killed. Cryosections (10 m) of the RA ST grafts were
examined using a fluorescence microscope with a
550-nm filter. Injection of CXCL16 or TNF (positive
control) into the engrafted RA ST prior to adoptive cell
transfer resulted in a significant increase of MNC mi-
gration (39) (Figure 5B). To ensure that cell recruitment
was induced by CXCL16 and not by contaminants, only
additive-free and sterile-filtered CXCL16 was used. In
addition, the soluble CXCL16 used in all experiments
contained 0.1 ng/g (1 endotoxin unit/g) endotoxin.
These results indicate that exogenously administered
CXCL16 is chemotactic for human MNCs in vivo.
Figure 5. A, A SCID mouse grafted with RA ST. Left, An area where
the RA ST graft was not inserted. Right, Side of the mouse where the
RA ST graft was inserted, clearly showing a viable, growing RA ST
graft (arrow). The photograph was taken 5 weeks after engraftment. B,
PKH26 red fluorescent dye–tagged human PB mononuclear cells (5 
106) were injected intravenously into SCID mice engrafted for 6–8
weeks with human RA ST. Before administering cells, ST grafts were
injected with TNF (200 ng/graft) or CXCL16 (1,000 ng/graft) or were
sham injected (no stimulus). After 48 hours, grafts were harvested and
tissue sections were examined by immunofluorescence microscopy at
550 nm. Top, PKH26 dye–tagged mononuclear cells (original magni-
fication  100). Bottom, Numbers of dye-tagged cells migrating to
engrafted RA ST in response to the various stimuli. Cell migration was
quantified by dividing the number of cells per high-power field (hpf).
Values are the mean and SEM (n  number of tissue sections
counted). See Figure 1 for other definitions. Color figure can be viewed in
the online issue, which is available at http://www.arthritisrheum.org.
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MNC chemotaxis to exogenously administered
intragraft CXCL16 is reduced by 50% to RA ST, and
5-fold to murine LNs, in cells transfected with antisense
ODNs for ERK-1/2. We further examined the participa-
tion of CXCL16 in the recruitment of MNCs in vivo by
inhibiting the signaling pathways it utilizes. To do this,
we transfected MNCs with sense or antisense ODNs for
ERK-1/2, and then we labeled the transfected cells with
PKH26 fluorescent dye. Before dye-tagging the cells, we
performed viability counts in order to make certain that
cells did not experience an increased rate of cell death.
Transfected dye-tagged cells were injected into tail veins
of SCID mice bearing RA ST receiving simultaneous
intragraft injections of CXCL16. Engrafted RA ST and
murine inguinal LNs were removed 48 hours later.
Transfection with antisense ODNs resulted in significant
reductions of MNC migration compared with sense-
treated controls (Figures 6A and B). The attenuated
migration to LNs was especially impressive considering
the elevated mean  SEM concentrations of soluble
Figure 6. Intravenous administration of fluorescent dye–tagged hu-
man mononuclear cells to SCID mice engrafted with human RA ST.
A, Fluorescent human mononuclear cells lipofected with sense (S)
oligodeoxynucleotides (ODNs) to ERK-1/2 migrated readily to en-
grafted human RA ST in response to an intragraft injection of human
CXCL16, whereas those cells lipofected with antisense (AS) ODNs to
ERK-1/2 showed reduced migratory activity. B, Fluorescent human
mononuclear cells lipofected with sense ODNs to ERK-1/2 migrated
readily to murine lymph nodes (LNs) in response to an intragraft
injection of human CXCL16, whereas those cells lipofected with
antisense ODNs to ERK-1/2 showed reduced migratory activity.
Values in A and B are the mean and SEM (n  number of tissue
sections counted from 3 mice per group). C, Mononuclear cells
transfected with antisense ODNs to ERK-1/2, but not nontransfected
(NT) or sense-transfected mononuclear cells, showed significant inhi-
bition of p–ERK-1/2 expression. D, A significant percentage of mono-
nuclear cell inhibition of ERK-1/2 expression using antisense ODNs to
ERK-1/2 is shown compared with sense-transfected mononuclear cells.
Values are the mean and SEM. The experiment was repeated 3 times.
-actin served as the loading control. hpf  high-power field (see
Figure 1 for other definitions). (Original magnification  100.) Color
figure can be viewed in the online issue, which is available at
http://www.arthritisrheum.org.
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human CXCL16 in the serum of mice receiving intra-
graft injections of CXCL16 (CXCL16-injected mice
1.91  0.23 ng/ml, n  7 mice; noninjected mice 0.84 
0.21 ng/ml, n  6 mice) (P  0.05) (data not shown).
To ensure that ERK-1/2 expression was inhibited
by antisense ODNs, we performed Western blot analysis
for ERK-1/2 expression in MNCs as described in Pa-
tients and Methods. As shown in Figure 6C, MNCs
transfected with antisense ODNs to ERK-1/2, but not
nontransfected or sense-transfected MNCs, showed sig-
nificant inhibition of ERK-1/2 expression. These data,
graphed in Figure 6D, show a significant percentage of
MNC inhibition of ERK-1/2 expression using antisense
ODNs to ERK-1/2 compared with sense-transfected
MNCs. These results show that targeting CXCL16-
mediated signaling pathways influences MNC migration
to RA ST and regional LNs in vivo.
DISCUSSION
Substantial progress in characterizing chemo-
kines and chemokine receptor function in vitro has led
to better understanding of cell migration (3,5,11,32), but
the limitations of the in vitro environment make it
difficult to interpret how chemokines and corresponding
receptors function in vivo. Limitations of in vitro migra-
tion assays include evaluating the role of a particular
chemokine as it relates to other chemokines and chemo-
kine receptors, and ranking the importance of chemo-
kines and chemokine receptors in a particular disease.
Indeed, many investigators have used a similar SCID
mouse chimera to study the effects of gene therapy and
RA ST fibroblast infiltration in vivo (41–43). Therefore,
to evaluate the proinflammatory function of chemokines
in RA, we developed an in vivo cell migration assay to
determine the relative importance of chemokines and
their respective cellular receptors in a human RA ST–
SCID mouse chimera.
Manipulation of chemokines has shown promise
for RA therapy. We previously showed that ENA-78, a
CXC chemokine, is up-regulated in RA SF as well as in
a rodent model of arthritis (22,44). Immunodepletion of
human ENA-78 resulted in decreased ability to che-
moattract polymorphonuclear cells in vitro (22). Fur-
thermore, anti–ENA-78 given systemically ameliorated
signs and symptoms of rat AIA (44). Inhibition of CC
chemokines also reduced joint inflammation. For exam-
ple, in vivo inhibition of the CC chemokine MIP-1 by
IL-10 delayed the onset and reduced the severity of
collagen-induced arthritis (CIA) in mice (45). A neutral-
izing antibody to MCP-1, another CC chemokine, sig-
nificantly reduced ankle swelling in a rat model of RA
(46). Chemokine antagonists have similarly shown
promise. For instance, a 67–amino acid sequence of
MCP-1 that specifically antagonizes MCP-1 abrogated
arthritis in MRL-lpr autoimmune mice, and an antago-
nist of RANTES ameliorated CIA in mice (47–49). IL-1
receptor antagonist protein, a naturally produced spe-
cific antagonist of IL-1, has consistently shown potent
antiinflammatory properties in animal models of inflam-
mation (50–52) and is used in the treatment of RA
(53–58). CXCL16 is a novel chemokine that has not
been fully characterized in chronic disease, and it is
especially of interest because its only known receptor to
date has been shown to be highly expressed in chronic
Th1 diseases such as RA (28).
Initial reports on CXCL16 in mice and humans
showed predominant gene expression in spleen, LNs,
and Peyer’s patches, with little or no expression in other
organs (24). Immunohistologic analysis revealed that
macrophages in RA ST stained intensely for both
CXCL16 and CXCR6. This staining is consistent with a
recent report that CXCL16 is produced by macrophages
(59). This was also confirmed by real-time RT-PCR
analysis showing elevated CXCL16 mRNA in RA ST
compared with OA and normal ST. CXCL16 was also
strongly expressed on a subset of PB leukocytes, includ-
ing CD14 monocytes and macrophages, from which
functional CXCL16 has been shown to be shed (25).
These findings are completely consistent with FACS
results indicating that 40% of CD14 monocytes and
33% of memory CD4 and CD8 lymphocytes express
CXCR6 in RA SF. The FACS results suggest that both
monocytes and lymphocytes may use the CXCR6 recep-
tor to migrate from the normal PB to the joints in
response to CXCL16 expression.
In combination with expression of its receptor
Bonzo/CXCR6 on T cell subsets, these results suggest a
unique role for CXCL16 in chronic inflammation. Re-
cent studies showing expression of both CXCL16 and its
receptor on T lymphocytes, akin to IL-2 and its receptor,
point to a possible mechanism of autocrine stimulation
(60). Our LN data support this role for CXCL16 as a
possible T lymphocyte regulatory factor. We observed
elevated serum levels of CXCL16 when CXCL16 was
injected intragraft into SCID mice (data not shown),
explaining in part the impressive recruitment of MNCs
to murine LNs.
RA patient data show that CXCL16 is highly
expressed in RA SF, is a potent chemoattractant for
MNCs in vitro, and is chemotactic for PBMCs to RA ST
in vivo. These findings suggest that inhibition of CXCR6
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expression or CXCL16 signaling pathways may substan-
tially halt migration of inflammatory cells to RA ST. Our
hypothesis was formulated on the basis of strong prelim-
inary data suggesting that CXCL16 is abundant in
chronic inflammation and may be associated with type 1
inflammatory responses (28). We have reason to believe
that although CXCL16 may play a dominant role in RA,
it may very well be important in other chronic diseases
such as OA, since we observed elevated mRNA expres-
sion of CXCL16 in OA compared with normal ST, and
elevated soluble CXCL16 in OA SF compared with
normal serum. Chandrasekar et al (61) demonstrated
that CXCL16 signals via Gi, PI 3-kinase, Akt, IB
kinase, and NF-B in aortic smooth muscle cells, point-
ing to specific signaling pathways after CXCL16–
CXCR6 binding. We found that stimulation of mono-
cytes with CXCL16 induced dose-dependent increases
in phosphorylation of the signaling molecules Raf and
ERK-1/2. This correlates with in vitro MNC migration
assays. For example, in the presence of ERK-1/2 signal-
ing pathway inhibitors, CXCL16-induced MNC migra-
tion was significantly blocked. Interestingly, FACS ana-
lysis showed that normal PB CD14 monocytes had
little or no expression of CXCR6.
These findings may indicate that other yet-
unknown receptors may also bind and respond to
CXCL16. Indeed, our observation of robust in vitro
recruitment of PB monocytes toward CXCL16 may be
the result of monocytes using an alternative receptor for
CXCL16. Also, it is possible that in the inflammatory
milieu of the RA SF, SF monocytes predominantly use
the CXCR6 receptor while inactivated PB monocytes
use another receptor. Our data cannot completely rule
out this possibility. We recently observed a similar
phenomenon with MIP-3, finding that PB monocytes
do not express the only known receptor for MIP-3,
namely, CCR6, but that they readily migrate dose de-
pendently toward MIP-3 in vitro (5).
We tested the capacity of CXCL16 to recruit
MNCs in vivo using the human RA ST–SCID mouse
chimera. This model has been used successfully by other
groups to show that engrafted RA ST not only keeps
many of the morphologic and pathologic characteristics
of RA ST (62), but also can be used as an appropriate
model of RA (63). We found that tail vein–injected cells
migrate to engrafted RA ST and murine LNs in re-
sponse to intragraft injections of human CXCL16. We
examined possible signaling mechanisms underlying this
response. We found that preincubation of MNCs with
antisense ODNs against ERK-1/2 resulted in a pro-
nounced decline in cell recruitment to engrafted RA ST
and inguinal LNs in CXCL16-injected SCID mice. Al-
though other signaling pathways may certainly be in-
volved, we report here that inhibition of a chemokine-
induced signaling cascade can temper the inflammatory
infiltrate in vivo.
These findings have twofold importance. First,
we observed an increase in MNC migration in response
to exogenously added chemokine. Second, the primary
function of this chemokine could be reversed in vivo by
inhibiting its signaling cascade. CXCL16 may have che-
motactic potency apart from other chemokines shown to
be expressed in RA (1–3,5,6,14,16,21–23,44,64). This is
supported by the finding that CXCL16 may function
independently of TNF and IL-1, at least in vitro. This
was initially unexpected, considering the potent proin-
flammatory activity of these cytokines in RA (8). We
found that cultured RA ST fibroblasts constitutively
produce large amounts of CXCL16 (1 ng/ml), explain-
ing in part the highly elevated levels of CXCL16 in RA
SF. Previous reports show that TNF further stimulates
RA synovial fibroblasts to release a variety of chemo-
kines, suggesting that cell recruitment is largely due to
TNF, and implicating TNF as an ultimate down-
stream eliciting agent (3,5).
Interestingly, we found that incubation of RA ST
fibroblasts with either TNF or IL-1 failed to further
increase CXCL16 expression, contrary to previous find-
ings with fractalkine and MIP-3 (3,5). This is especially
important when considering the amounts of CXCL16
found in patient samples, reaching levels as high as 145
ng/ml in some cases. It suggests that large amounts of
CXCL16 may be produced in RA independently of
established proinflammatory cytokines. This finding is
consistent with results of a recent study showing that RA
fibroblasts express CXCL16 directly when stimulated by
way of the Toll-like receptor 2 ligand peptidoglycan (65).
In conclusion, we evaluated the expression and
function of CXCL16 and its receptor CXCR6 in RA. We
found both the ligand and receptor to be very highly
expressed in RA, and we observed that CXCL16 func-
tions to aggressively recruit MNCs in vivo via the Raf
and ERK-1/2 kinase pathways. These results point to
CXCL16 as a novel, potent MNC recruiter in RA
inflammation.
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